146
Participants
Start Date
July 15, 2022
Primary Completion Date
March 29, 2026
Study Completion Date
March 29, 2026
PD-1 inhibitor+GP
PD-1 inhibitor (200-240mg), gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
GP
Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
The First Affiliated Hospital of Guangxi Medical University, Nanning
Hainan People's Hospital
OTHER
Wuzhou Red Cross Hospital
OTHER
First People's Hospital of Yulin
OTHER
Fourth Affiliated Hospital of Guangxi Medical University
OTHER
Guigang People's Hospital
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Yunnan Cancer Hospital
OTHER
LiuZhou People's Hospital
OTHER
Affiliated Hospital of North Sichuan Medical College
OTHER
Guangxi Medical University
OTHER